Freeline touts positive data for Gaucher disease therapy – Pharmaceutical Technology
Freeline’s gene therapy FLT201 introduces a transgene to produce an engineered GCase variant, the enzyme responsible for the symptoms of Gaucher disease. Credit: dizain via